Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Leukemia Research, 2001; 25(12):1047-1050||en|
|dc.description.abstract||Cancer patients may make antibodies against antigens on the surface of their malignant cells due either to the expression of unique antigens or to dysregulated responses to self antigens. Patients with B cell malignancy frequently produce autoantibodies and may therefore be a source of immunoglobulin genes for the production of phage display antibody libraries directed against tumour-associated antigens. Patients with autoimmune disease have circulating antibodies against lymphocyte surface antigens, and may also provide a good starting point for the production of a library of lymphocyte-reactive antibody structures. In this study, plasma and serum samples from patients with B cell malignancy or Sjogren's syndrome and from healthy controls were screened for antibodies against the B cell membrane antigens CD20. While the majority of samples showed very low reactivity, some individuals did show significant and reproducible binding to CD20. To identify a good donor for library construction, it would be advisable to screen donors for antibody against the antigens of interest.||en|
|dc.publisher||Pergamon-Elsevier Science Ltd||en|
|dc.subject||Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peptide Library; Antigens, CD20; Autoantibodies; Enzyme-Linked Immunosorbent Assay; Leukemia, Lymphocytic, Chronic, B-Cell||en|
|dc.title||Antibody against CD20 in patients with B cell malignancy||en|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.